PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers
Squibb Company (NYSE: BMY) today announced new results from the
Phase 3 CheckMate -214 study, showing that therapy with Opdivo
(nivolumab) plus low-dose Yervoy (ipilimumab) continued to
demonstrate long-term survival benefits in patients with previously
untreated advanced or metastatic renal cell carcinoma (RCC).
Ticker: BMY Exchange: NYSE
$BMY announces long-term survival data in metastatic renal cell carcinoma at #GU19. #RCC #KidneyCancer #KCSM